Litigation Details for WARNER CHILCOTT COMPANY, LLC v. AMNEAL PHARMACEUTICALS, LLC. (D.N.J. 2012)

WARNER CHILCOTT COMPANY, LLC v. AMNEAL PHARMACEUTICALS, LLC. (D.N.J. 2012)

Docket	3:12-cv-02928	Date Filed	2012-05-16
Court	District Court, D. New Jersey	Date Terminated	2014-01-17
Cause	35:271 Patent Infringement	Assigned To	Joel A. Pisano
Jury Demand		Referred To	Tonianne J. Bongiovanni
Patents	7,704,984
Link to Docket	External link to docket

Details for WARNER CHILCOTT COMPANY, LLC v. AMNEAL PHARMACEUTICALS, LLC. (D.N.J. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-05-16				External link to document

Warner Chilcott v. Amneal Pharmaceuticals, 3:12-cv-02928: Doryx Patent Litigation Summary

Last updated: August 2, 2026

Warner Chilcott Company, LLC v. Amneal Pharmaceuticals, LLC, No. 3:12-cv-02928, was an abbreviated new drug application, or ANDA, patent case concerning generic doxycycline delayed-release tablets corresponding to Warner Chilcott's Doryx product. Warner Chilcott asserted patents covering delayed-release doxycycline formulations and sued after receiving Amneal's Paragraph IV certification. The case was resolved through a settlement and did not produce a merits decision invalidating or upholding the asserted patents.

What drug and patents were involved in Warner Chilcott v. Amneal?

The litigation concerned Doryx, a delayed-release oral doxycycline product. Doryx was marketed for acne and other infections for which doxycycline was appropriate. The product used a controlled-release formulation designed to delay release of doxycycline in the gastrointestinal tract.

Product and regulatory information

Item	Information
Brand product	Doryx
Active ingredient	Doxycycline, generally doxycycline hyclate
Dosage form	Delayed-release tablets
Regulatory pathway	ANDA litigation under the Hatch-Waxman Act
Plaintiff	Warner Chilcott Company, LLC
Defendant	Amneal Pharmaceuticals, LLC
Court	U.S. District Court for the District of New Jersey
Case number	3:12-cv-02928
Case type	Patent infringement under 35 U.S.C. § 271(e)(2)
Resolution	Settlement and dismissal
Trial outcome	No reported merits judgment

Warner Chilcott's complaint challenged Amneal's proposed generic Doryx product. The asserted patents were associated with the delayed-release doxycycline formulation and included U.S. Patent Nos. 6,958,161 and 7,232,572, which were among the principal Doryx formulation patents identified in related litigation and regulatory records.

The central legal issue was whether Amneal's ANDA product would infringe claims directed to the composition, release characteristics, and manufacturing or formulation structure of Doryx.

How did the Paragraph IV challenge trigger the litigation?

Amneal's ANDA included a Paragraph IV certification asserting that one or more Doryx patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Warner Chilcott responded by filing suit within the statutory 45-day period.

A Paragraph IV certification creates an artificial act of infringement under 35 U.S.C. § 271(e)(2). The statutory purpose is to permit the patent holder to litigate before commercial launch. Filing the action generally triggers a 30-month stay of FDA approval, subject to statutory exceptions and court orders.

The case therefore presented two separate issues:

1. Whether Amneal's proposed doxycycline delayed-release product infringed the asserted claims.
2. Whether the patents could withstand Amneal's validity and enforceability defenses.

The public case record does not reflect a final judicial determination on either issue.

What patents protected Doryx in the Amneal litigation?

The Doryx patent estate relied primarily on formulation and controlled-release protection rather than a simple composition-of-matter patent.

U.S. Patent No. 6,958,161

U.S. Patent No. 6,958,161 was directed to controlled-release pharmaceutical compositions. Its relevance was the use of a formulation architecture that controlled the location and timing of doxycycline release.

The patent's commercial significance came from its ability to protect a delayed-release doxycycline tablet even after basic doxycycline active-ingredient protection had expired. A generic manufacturer could not avoid the patent merely by using the same active ingredient. It needed to design around the claimed release system or prevail on invalidity or noninfringement.

U.S. Patent No. 7,232,572

U.S. Patent No. 7,232,572 was another Doryx-related controlled-release formulation patent. It addressed formulation characteristics relevant to delayed delivery and product performance.

The patent estate was commercially stronger than a single broad formulation patent because multiple claims and related patents could create cumulative litigation risk. The practical question for Amneal was whether its ANDA formulation reproduced the claimed release mechanism, coating structure, or other formulation limitations.

Patent expiration dates depended on statutory patent-term adjustments, terminal disclaimers, and any applicable regulatory extensions. The relevant Orange Book entries, not a generic expiration date stated in a litigation summary, control the FDA's listed patent information.

What was the litigation timeline?

Date or period	Event
Before 2012	Warner Chilcott marketed Doryx and maintained patent protection for delayed-release doxycycline formulations.
2012	Amneal submitted an ANDA containing Paragraph IV certifications concerning Doryx patents.
2012	Warner Chilcott filed Civil Action No. 3:12-cv-02928 in the District of New Jersey.
2012-2013	The parties litigated infringement, validity, and related Hatch-Waxman issues.
Settlement period	The parties resolved the dispute without a reported trial or final merits judgment.
Following settlement	The action was dismissed pursuant to the parties' agreement.

The settlement terms were not publicly disclosed in the case materials generally available through reported decisions. The public record does not establish an authorized launch date, a royalty structure, or a license scope with sufficient precision to state those terms as fact.

What was the legal theory in Warner Chilcott v. Amneal?

Warner Chilcott's infringement theory was based on the statutory submission of Amneal's ANDA and the proposed generic formulation. The asserted patents were formulation patents, so the case likely turned on technical characteristics of the generic product rather than on whether Amneal used doxycycline itself.

Formulation infringement

A delayed-release doxycycline product can infringe even if it uses a different trade name, tablet shape, excipient profile, or manufacturing site. The relevant analysis focuses on the patent claims and the product defined in the ANDA.

Potential claim elements included:

• A doxycycline-containing core or matrix.
• A release-delaying coating or barrier.
• Specific pH-dependent release behavior.
• Dosage-form architecture.
• Defined dissolution or release characteristics.
• Manufacturing steps needed to produce the claimed formulation.

In ANDA litigation, the court evaluates the product described in the ANDA, including its proposed manufacturing process and labeling. The product does not need to be commercially launched for infringement liability under § 271(e)(2).

Validity defenses

Amneal's Paragraph IV position would have permitted challenges based on:

• Anticipation under 35 U.S.C. § 102.
• Obviousness under 35 U.S.C. § 103.
• Lack of written description or enablement under 35 U.S.C. § 112.
• Indefiniteness.
• Noninfringement.
• Unenforceability, including inequitable conduct where supported by the record.

Delayed-release pharmaceutical patents often face obviousness challenges based on earlier controlled-release systems, conventional enteric coatings, known doxycycline formulations, and routine optimization of dissolution profiles. The patent holder's counterargument typically is that the claimed combination produces an unexpected release profile, solves a known tolerability or stability problem, or requires more than routine experimentation.

Because the matter settled, no binding court finding established the strength of either side's position.

What was the Orange Book status of Doryx?

Doryx was an FDA-approved delayed-release doxycycline product with patents listed in the Orange Book. Those listings provided the regulatory basis for Warner Chilcott's patent enforcement against ANDA applicants.

Orange Book listing has two important effects:

1. It gives an ANDA applicant a mechanism to make a Paragraph IV certification.
2. It can delay FDA approval through the statutory 30-month stay after timely patent litigation.

Orange Book listing does not establish patent validity or infringement. It is a regulatory notice mechanism. A listed patent may later be narrowed, invalidated, delisted, or rendered commercially less relevant by a design-around product.

The exact FDA approval timing for Amneal's product cannot be inferred solely from the lawsuit. A settlement may permit launch before patent expiration, but the agreement may impose a negotiated date, royalties, or other conditions.

Did Warner Chilcott obtain an injunction?

There was no reported final injunction after a merits trial in this case. The case ended through settlement and dismissal.

A Hatch-Waxman plaintiff does not automatically receive an injunction merely because it filed a patent action. Warner Chilcott would have needed to establish infringement and obtain appropriate relief, or negotiate launch restrictions through settlement. The dismissal therefore reflects private resolution rather than a judicial ruling that Amneal's product infringed.

What was the commercial significance of the case?

The case protected Warner Chilcott's ability to delay or control generic competition to Doryx. The commercial value came from the formulation barrier. Doxycycline itself was an established generic active ingredient, but a generic competitor still faced additional development and litigation risk if it sought to match Doryx's delayed-release presentation.

Revenue exposure

The litigation's revenue exposure was tied to:

• Doryx tablet sales during the remaining patent term.
• The number of Doxycycline strengths covered by the patents.
• The availability of competing delayed-release products.
• The timing of any authorized or independent generic launch.
• Price erosion after generic entry.
• Whether the generic was therapeutically substitutable for Doryx.

Doryx's commercial protection was weaker than the protection for a new chemical entity because doxycycline had long been available in generic forms. Its value depended on the delayed-release delivery system, brand prescribing, product differentiation, and the ability to preserve pricing against generic versions of the same formulation.

How strong was the Doryx patent estate?

The estate had moderate commercial strength but meaningful design-around risk.

Factors supporting Warner Chilcott

• The patents covered a differentiated delayed-release formulation.
• The patents could be asserted before generic launch through the ANDA process.
• Multiple formulation patents increased the cost of a complete design-around.
• Product-specific release characteristics could make noninfringement difficult if Amneal closely matched Doryx.

Factors supporting Amneal

• Doxycycline was a mature, well-known active ingredient.
• Controlled-release and enteric-release technologies had substantial prior art.
• Generic applicants could pursue alternative coatings, release mechanisms, or dissolution profiles.
• A settlement avoided the cost of trial and the risk of a launch delay.

The absence of a merits judgment means the case cannot be used as precedent confirming that the asserted Doryx claims were valid or infringed.

Did the settlement create a generic launch date?

The public litigation disposition does not establish a definitive generic launch date. Hatch-Waxman settlements commonly contain confidential or partially disclosed provisions concerning:

• Earliest licensed entry.
• Authorized generic arrangements.
• Royalty payments.
• Restrictions on manufacturing or distribution.
• Covenants not to sue.
• Patent challenges.
• Regulatory cooperation.

A dismissal alone does not show whether Amneal received an immediate license, a delayed license, or a license subject to commercial conditions. FDA approval and commercial launch also remain separate events.

What generic entry risks existed after the case?

The principal generic entry risks were formulation design-around, later ANDA filings, patent expiration, and regulatory changes.

Design-around risk

A generic manufacturer could reduce infringement risk by changing:

• Coating composition.
• Coating thickness.
• Release-triggering pH.
• Tablet manufacturing process.
• Doxycycline particle characteristics.
• Dissolution profile.
• Excipients and release-control materials.

A design-around could still face bioequivalence or therapeutic-equivalence requirements under FDA rules. A formulation that avoids the patent may not automatically satisfy the FDA's product-performance requirements.

Later applicants

A settlement with Amneal would not necessarily prevent other applicants from filing Paragraph IV certifications. Separate applicants could challenge the same patents, seek different claim constructions, or use different technical designs.

Patent expiration

Once the relevant patents expired, generic manufacturers no longer faced infringement liability for practicing the expired claims. FDA exclusivity, however, is distinct from patent protection. Any remaining regulatory exclusivity would need to be evaluated separately by reference to the applicable Doryx NDA and FDA records.

How does this case compare with biologic or small-molecule patent litigation?

Warner Chilcott v. Amneal was a small-molecule ANDA case, not a biosimilar dispute under the Biologics Price Competition and Innovation Act.

Issue	Doryx litigation	Biologic biosimilar litigation
FDA pathway	ANDA	351(k) biosimilar application
Product	Small-molecule doxycycline	Biological product
Primary dispute	Formulation, release, infringement	Platform, manufacturing, formulation, method, and biologic patents
Regulatory trigger	Paragraph IV certification	BPCIA patent-exchange process
Automatic stay	Hatch-Waxman 30-month stay framework	Different BPCIA timing and injunction framework
Interchangeability	Generic substitution rules	Separate interchangeability determination

Biosimilar risk was therefore not directly relevant to this case. The competitive threat came from generic doxycycline delayed-release tablets.

Key Takeaways

• Warner Chilcott sued Amneal in the District of New Jersey over an ANDA for generic Doryx.
• The case involved delayed-release doxycycline formulation patents, including U.S. Patent Nos. 6,958,161 and 7,232,572.
• Amneal's Paragraph IV certification created the Hatch-Waxman infringement action.
• The case settled and was dismissed without a reported trial or final merits judgment.
• The public disposition does not establish that the asserted patents were valid, infringed, or invalid.
• Doryx's principal protection was formulation-based, not a new-chemical-entity patent.
• Generic entry risk centered on formulation design-around strategies, later ANDA filings, patent expiration, and settlement restrictions.
• No definitive public launch date or complete settlement economics should be attributed to Amneal without the settlement agreement or a definitive regulatory record.

FAQs About Warner Chilcott v. Amneal

What was the case number for the Doryx patent lawsuit?

The case was Warner Chilcott Company, LLC v. Amneal Pharmaceuticals, LLC, No. 3:12-cv-02928, filed in the U.S. District Court for the District of New Jersey.

Was Amneal found to infringe the Doryx patents?

No final reported merits judgment established infringement. The case was resolved through settlement and dismissal.

Were the Doryx patents composition-of-matter patents?

The asserted patents were primarily formulation and controlled-release patents covering delayed-release doxycycline products, rather than broad composition-of-matter protection for doxycycline.

Did the lawsuit involve a biosimilar?

No. The dispute involved a small-molecule ANDA under the Hatch-Waxman Act, not a biosimilar application under the BPCIA.

Can another generic company challenge the same Doryx patents?

Yes. A settlement with one ANDA applicant does not necessarily prevent another applicant from filing a Paragraph IV challenge or pursuing a different noninfringing formulation.

References

1. U.S. District Court for the District of New Jersey. (2012). Warner Chilcott Company, LLC v. Amneal Pharmaceuticals, LLC, No. 3:12-cv-02928.

2. U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,958,161: Controlled-release pharmaceutical compositions.

3. U.S. Patent and Trademark Office. (2007). U.S. Patent No. 7,232,572: Controlled-release pharmaceutical compositions.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

5. U.S. Code. (2024). 21 U.S.C. § 355(j).

6. U.S. Code. (2024). 35 U.S.C. § 271(e)(2).